Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 425 of 496 entries
View as:

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Phase: N/A Priority: Normal
NCT ID: NCT03558152 Org: User:
Start: 10/26/18 End: 12/15/21 Due: 12/15/22

A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Phase: N/A Priority: Normal
NCT ID: NCT00968981 Org: User:
Start: 09/30/09 End: 10/31/10 Due: 10/31/11

A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04434469 Org: User:
Start: 07/08/20 End: 02/23/22 Due: 02/23/23

A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00443651 Org: User:
Start: 01/31/07 End: 02/28/13 Due: 02/28/14

A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

Phase: N/A Priority: Normal
NCT ID: NCT01998841 Org: User:
Start: 12/20/13 End: 08/08/23 Due: 08/08/24

A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)

Phase: N/A Priority: Normal
NCT ID: NCT00388206 Org: User:
Start: 11/30/06 End: 03/31/12 Due: 03/31/13

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

Phase: N/A Priority: Normal
NCT ID: NCT00833963 Org: User:
Start: 01/14/09 End: 04/13/17 Due: 04/13/18

A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05243342 Org: User:
Start: 04/28/22 End: 07/10/24 Due: 07/10/25

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05487235 Org: User:
Start: 08/17/22 End: 03/31/26 Due: 03/31/27

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02091141 Org: User:
Start: 04/14/14 End: 05/24/23 Due: 05/24/24

A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)

Phase: N/A Priority: Normal
NCT ID: NCT00866788 Org: User:
Start: 03/31/09 End: 01/31/10 Due: 01/31/11

An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)

Phase: N/A Priority: Normal
NCT ID: NCT01604252 Org: User:
Start: 06/20/12 End: 04/28/17 Due: 04/28/18

A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02092792 Org: User:
Start: 04/01/14 End: 07/10/17 Due: 07/10/18

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-Obstructive Disease

Phase: N/A Priority: Normal
NCT ID: NCT06603246 Org: User:
Start: 11/18/24 End: 09/15/26 Due: 09/15/27

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01283373 Org: User:
Start: 03/31/11 End: 01/31/16 Due: 01/31/17

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03451162 Org: User:
Start: 04/17/18 End: 07/16/21 Due: 07/16/22

A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT00729768 Org: User:
Start: - End: - Due: -

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01125748 Org: User:
Start: 05/31/10 End: 08/31/13 Due: 08/31/14

A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT00243412 Org: User:
Start: 08/31/05 End: 02/28/09 Due: 02/28/10

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02271139 Org: User:
Start: - End: - Due: -

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04449874 Org: User:
Start: 07/29/20 End: 02/28/26 Due: 02/28/27

A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

Phase: N/A Priority: Normal
NCT ID: NCT01545453 Org: User:
Start: 03/31/12 End: 07/31/13 Due: 07/31/14

An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT03154437 Org: User:
Start: - End: - Due: -

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01186991 Org: User:
Start: 03/31/11 End: 03/31/16 Due: 03/31/17

A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02092831 Org: User:
Start: 04/30/14 End: 05/31/14 Due: 05/31/15